Adjunctive treatment in COVID-19 and sepsis-What did we learn?

ABSTRACT: The introduction of anakinra, baricitinib and tocilizumab into the treatment armamentarium of severe coronavirus disease 2019 (COVID-19) reinforced the concept of immunotherapy for bacterial sepsis. The current review investigates how the example of COVID-19 may be extrapolated to sepsis using a three-step approach. In the first step, the clinical evidence on how the immunotherapy of COVID-19 assisted viral clearance is presented. In a second step, the indications acquired from human and animal studies on the need to employ strategies with primary effective phagocytosis in sepsis are presented. In a final step, lessons learnt from COVID-19 immunotherapy are applied for sepsis. The end result is that sepsis immunotherapy should rely on the use of biomarkers which provide information on the

SUBMITTER: Giamarellos-Bourboulis EJ 

PROVIDER: S-EPMC10733190 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature